德孚在中国

9 7 2 2 7

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

普纳替尼，一个多靶向酪氨酸激酶抑制剂，对抗人类 U87 恶性胶质瘤细胞的影响

 

Authors Zhang J, Zhou Q, Gao G, Wang Y, Fang Z, Li G, Yu M, Kong L, Xing Y, Gao X

Published Date October 2014 Volume 2014:7 Pages 2013—2019

DOI http://dx.doi.org/10.2147/OTT.S67556

Received 11 May 2014, Accepted 30 July 2014, Published 30 October 2014

Approved for publication by Dr Faris Farassati

Abstract: Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells.
Keywords: cancer therapy, glioma, glioblastoma multiforme






Download Article[PDF]